(Q33809456)

29 July 2017

1 reference

title

Clinical significance of hepatitis C virus genotypes. (English)

1 reference

29 July 2017

1 reference

1 reference

Mondelli MU

1

1 reference

PubMed ID

10622563

29 July 2017

Silini E

series ordinal

2

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

Journal of Hepatology

1 reference

29 July 2017

31 Suppl 1

1 reference

29 July 2017

65-70

1 reference

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Genotypic analysis of hepatitis C virus in American patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Molecular epidemiology of hepatitis C virus infection among intravenous drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Detection and typing of hepatitis C RNA in liver biopsies and its relation to histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

HCV genotypes in patients with liver disease of different stages and severity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes and development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes and reinfection of the graft during long-term follow-up in 35 liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

The influence of hepatitis C virus genotypes on the outcome of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Clinical characteristics and antibody profiles of chronic hepatitis C patients: relation to hepatitis C virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

Combination therapy for hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980377-8

7 January 2021

10.1016/S0168-8278(99)80377-8

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10622563